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ABSTRACT 
Purpose of the review: Antiphospholipid syndrome (APS) is defined as the association of 
thrombotic events and/or obstetric morbidity in patients persistently positive for 
antiphospholipid antibodies (aPL). In this review we will highlight the most important clinical 
presentations ofAPS with a focus on the obstetric morbidity, the current management 
strategies and the outlook for the future.  
Recent findings: The use of aspirin and heparin has improved the pregnancy outcome in 
obstetric APS and approximately 70% of pregnant women with APS have a successful 
pregnancy outcome. Unfortunately, the current standard of care does not prevent all 
pregnancy complications as the current treatment fails in 20-30% of APS pregnancies. This 
therefore highlights the need for alternative treatments to improve obstetrical 
outcome.Other treatment options are currently explored and retrospective studies show 
that pravastatin for example is beneficial in women with aPL related early preeclampsia. 
Moreover, the immunmodulator hydroxychloroquine (HCQ) may play a beneficial role in the 
prevention of aPL related pregnancy complications. 
Summary: APS is amongst the most frequent acquired risk factors for a treatable cause of 
recurrent pregnancy loss and increases the risk of conditions associated with ischaemic 
placental dysfunction, such as fetal growth restriction, pre-eclampsia (PET), premature birth 
and intrauterine death. Current treatment is mainly based on aspirin and heparin. Studies to 
inform on alternative treatment options are urgently needed.  
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INTRODUCTION(2993 words) 
Antiphospholipid syndrome (APS) is classified as the association of arterial and/or venous 
thromboses and/or obstetric morbidity in patients who test positive for antiphospholipid 
antibodies (aPL) on two occasions at least 12 weeks apart. Antibodies currently included in 
the APS classification criteria are lupus anticoagulant (LA), IgG and/or IgM anti-cardiolipin 
(aCL) and/or IgG and/or IgM anti-beta2glycoprotein1 antibodies (anti-beta2GP1)1.The 
classification criteria for APS, which often also guide diagnosis, were originally outlined in 
the Sapporo criteria and were updated in 2006 and are now referred to as the Sydney 
criteria1,2.  
 
Initially, the association of circulating lupus anticoagulant (LA) and anticardiolipin antibodies 
(aCL), thrombosis, pregnancy loss and thrombocytopenia was described in women suffering 
from systemic lupus erythematosus (SLE)3. This has resulted in that APS in patients with SLE 
has been referred to as ‘secondary’, but it is now widely accepted that APS is an 
autoimmune entity of its own, and that it may well exist in the absence of SLE4.  
APS isone of the main acquired prothrombotic conditions that predisposes to venous 
thromboembolism (also referred to as ‘thrombophilia’). Unlike the other thrombophilias, it 
is unique for APS, that is can also predispose to arterial and microvascular thrombosis. 
The other hallmark of this syndrome is pregnancy morbidity, which includes recurrent first 
trimester pregnancy loss, intrauterine growth restriction (IUGR), pre-eclampsia (PET), 
premature birth and intrauterine death (IUD)1,5.Data from a retrospective cohort of 500 
women with a history of recurrent first trimesterpregnancy loss suggested that 26.4% are 
associated with the presence of aPL6. aPL related PET, premature birth or fetal loss are seen 
in 10–20% of APS pregnancies 7. In view of these pregnancy complications, APS has been 
referred to as the most frequent acquired risk factor for a treatable cause of recurrent 
pregnancy loss8.  
The current standard of treatment ofAPS is mainly relying on antithrombotic and anti-
aggregation treatment9.The combination of low dose aspirin (LDA) and heparin 
(unfractionated heparin (UF) or low molecular weight heparin (LMWH)) has resulted in a live 
birth rate of 70-80%10. 
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Recent data suggest a role for drugs including hydroxychloroquine11,12 and pravastatin13, but 
their efficacy and safety in the setting of aPL pregnancies requires confirmation in 
prospective randomised controlled trials14.  
The potential beneficial role of pravastatin was highlighted in a retrospective case control 
study on patients with manifest aPL-related PET and/or IUGR on standard treatment with 
LDA and LMWH13. Moreover,the immunmodulator hydroxychloroquine (HCQ) is currently 
the centre for attention not only in thrombotic but also obstetric APS. Retrospective data 
suggest, that HCQ reduces the risk of thrombosis in APS15and also improves pregnancy 
outcomes in women with aPL-related pregnancy complications12,16. Upcomingrandomised 
controlled trials will hopefully provide the answer in the near future17.  
 
ANTIPHOSPHOLIPID ANTIBODIES 
aPL are a heterogeneous group of antibodies and can be detected in three different ways. 
Theavailable and required assays detect lupus anticoagulant (LAC), anticardiolipin antibodies 
(aCL) and anti-β2glycoprotein-I (aβ2GPI) and patients may be positive for one, two or three 
of these tests1. The type of aPL, the titre level and the presence of multiple antibodies has 
been associated with different risk profiles. LAC for example has been described asthe best 
predictor for pregnancy loss and thrombosis18. Some authors suggest that the aPL titre is of 
clinical interest19, especially in aPL-related pregnancy complications where low to medium 
titre antibodies have been suggested to be of clinical relevance19. Regarding the individual 
specific immunoglobulin isotypes, a positive aCL IgG has been associated to a higher risk of 
adverse pregnancy outcomes compared to IgM and IgA seems not to be an independent 
predictor20. Galli et al. published a systematic review including 63 studies and concluded that 
LAC (and aCL IgG) is the strongest risk factor for thrombosis 18.The presence of all three 
antibodies (referred to as ‘triple positive’ patients) seem to be associated with a high risk for 
thrombotic APS21.  
Conversely, there is increasing evidence that patients with low aPL titres can experience 
poor pregnancy outcomes similarly to high-titre patients19,22,23.These observations suggest 
that, in contrast to thrombotic events, low-titer aPLs can play a significant role in OAPS and 
that the actual classification criteria do not include all the OAPS cases. 
For more specific details on aPL included in the current classification criteria can be read in 
detail elsewhere24. 
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PATHOGENESIS 
Thrombosis and fetal loss  
aPL have the unique ability to induce thrombus formation in the arterial and/or venous  
vasculature  and/orthe microcirculation25-27.The exact mechanism by which aPL cause 
prothrombotic changes has been debated, but remains as yet fully explained. aPLhave 
thepotential to activate several cell types involved in haemostasis including endothelial cells, 
monocytes and platelets 28. Other experiments have shown that some aPL are able to inhibit 
fibrinolysis and the protein C pathway 29. It is therefore not surprising, that placental 
thrombosis impairing the maternal–fetal blood exchange has been suggested to play a major 
role in obstetric APS. Moreover it has been reported that aPL are able to disrupt the 
anticoagulant annexin A5 shield on trophoblast and endothelial cell monolayers, resulting in 
fetal loss 30,31. Ultimately it maybe that multiple mechanisms are responsible for aPL causing 
thrombosis in one individual. 
Placental infarctions were initially thought to be the main cause of fetal loss. However, they 
werenot the universal histopathological findings in human placental samplesand other 
mechanisms have therefore been proposed to underlie the pathophysiology of obstetric 
APS32.De Wolf et al. for example showed that in placental tissues of LAC positive 
patients,evidence of thrombosis in the placental bed and alsosigns of acute and chronic 
inflammation 33. These findings were in line with a study by Stone et al. who found increased 
infiltration of inflammatory cells, particularly macrophages in placentae of women with aPL 
34.  
Moreover, it is very likelythat the pathogenesis of aPL-related recurrent pre-embryonic 
lossdiffers from the pathogenesis of morbidity occurring in late pregnancy35.aPL have direct 
pathogenic effects on placentationand apoptosis of trophoblast cells, which may play an 
important role, particularly recurrent first trimester losses36. This association is supported by 
murine models, which suggest that the complement system is the key mediator of aPL-
related pregnancy loss and fetal growth restriction. In a pregnant murine model based on 
BALB/c mice and FcRy mice,mice infused with aPL had increased fetal losses and exhibited 
fetal growth restriction. Mice with complement deficiency or complement blockage showed 
protection against aPL induced pregnancy complications, as did treatment with heparins 
(which have an anti-complement effect) as opposed to fondaparinux with no anti-
complement effect37,38. Increased complement deposition product were observed in the 
decidua of pregnant mice infused with aPL, whereas mice depleted of neutrophils or mice 
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treated with heparin did not show pregnancy loss or growth restriction and there was a lack 
of complement deposition in their decidual tissue37. The findings from these animal studies 
were supported by human studies by Shamonki et al., who showed that placentae of women 
with aPL have increased complement deposition39. Thus it is now widely accepted that both 
thrombosis and inflammation seem to mediate aPL-related ischemic placental pregnancy 
complications in women with aPL 24. 
 
CLINCAL MANIFESTATIONS OF THE ANTIPHOSPHOLIPID SYNDROME  
Thrombotic APS  
As mentioned above, aPL related thrombosis can occur in any vascular bed1. The most 
frequentarterial manifestations are neurological manifestations such as stroke or transient 
ischaemic attacks (TIA), whereas the most common venous thromboembolic manifestation 
include deep vein thrombosis (DVT) and pulmonary embolism (PE) 7.  
Other manifestations including retinalartery or vein thrombosis, amaurosis fugax, renal 
thrombotic microangiopahty,pulmonary hypertension and vascular dementia are seen less 
frequent in 10% of patients, whereas adrenal haemorrhage, avascularnecrosis, pathological 
bone fractures due to bony infarcts or Budd-Chiari Syndromeare seen in 1% of APS 
patients40. Livedo reticularis, the most common skin manifestation, is sometimes 
associatedtoocclusive arterial events in the brain and referred to as Sneddon’s syndrome7,41. 
The most life-threatening clinical manifestation is rare and referred to as catastrophic APS 
(CAPS). CAPS is classified by thrombosis in at least three organs often accompanied by small 
vessel thrombosis developing over a short period and is associated with a mortality of over 
50%4243. 
Non-thrombotic APS manifestations can include thrombocytopenia, which is usually 
associated with a risk of thrombosis rather than bleeding complications; cardiac valve 
abnormalities – minor thickening &/or incompetence due to valve thrombosis. The valves 
rarely cause haemodynamic consequences. 
 
Obstetric APS  
Recurrent early miscarriages  
The obstetric manifestations include recurrent first trimester pregnancy loss, and conditions 
associated with ischaemic placental dysfunction such asintrauterine death, stillbirth, 
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PET,premature birth and FGR affecting up to 10 - 20% of APS pregnancies140. Unfortunately, 
the definition of miscarriage varies which makes the comparison of reported studies 
challenging. In Europe, the most widely used definition for early miscarriage is pregnancy 
loss within the first 12 completed weeks of pregnancy. Ten to 15% of all clinically recognised 
pregnancies end inthis way44. The most common reasons for early miscarriage and recurrent 
miscarriages are genetic abnormalities, cervical weakness, anatomic variations,endocrine 
factors and immune factors, such as thyroid factors, infective agents i.e. TORCH 
(Toxoplasmosis, Other, Rubella, Cytomegalovirus, Herpes simplex virus) and aPL 45.In a 
cohort of 500 women with a history of recurrent miscarriages Rai et al found 9.6% of women 
to be persistently positive for LA, whereas aCL IgG and IgM were found in 3.3% and 2.2%, 
respectively 6. The prevention of recurrent early miscarriages is the only area in obstetric 
APS, in which treatment is based on several clinical trials, including randomised controlled 
trials. This will be discussed in more depth under management.  
 
Late pregnancy loss 
Late pregnancy loss or fetal death is defined as pregnancy loss after 10 weeks of gestation, 
whereas stillbirth indicates a loss after 20 weeks by some although the definition 
recommended by WHO for international comparison is a baby born with no signs of life at or 
after 28 weeks' gestation. The only population based study (the stillbirth collaborative 
research network) reported the association of aPL (aCL and anti-β2GPI) with a significant 
increased odds of stillbirth (3-5 fold) in 582 cases of fetal death beyond 20 weeks of 
gestation. However, the group did not measure LAC, and aCl were not reassessed after 12 
weeks interval to confirm persistency of the aPL46.  
 
Placental insufficiency and pre-eclampsia (PET) 
PET and/or placental insufficiency can manifest as fetal growth restriction (FGR) and occurs 
in about 2-8% of mainly first pregnancies, whilst severe PET is found in 0.5% of pregnancies 
in developed countries. Most prospective observational studies support the association of 
aPL with PET and placental insufficiency. A recent systematic meta-analysis showed that 
moderate to high levels aCL are associated with PET47. Moreover, several prospective and 
retrospective studies have shown that the persistent presence of high-titre aPL are 
associated with FGR and preterm deliveries40,48,49. Datafrom case control studies have shown 
that amongst patients with a history of PET or FGR, aPL were found in up to 50%, compared 
to 7% or less in healthy pregnant women50. There is to date only one randomised controlled 
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trial assessing the management and prevention of PET and FGR in women with aPL. The aim 
of the multicentre study (FRUIT-RCT)was to examine if combined treatment with low-
molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders 
(HD) of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with aPL 
with a previous delivery for HD and/or small-for-gestational-age (SGA) birth weight before 
34 weeks gestation51. Unfortunately, the study was terminated due tovery low event rates 
and the final analysis on 33 (recruitment target was 85 women to detect a 50% risk 
reduction) women did not show any significant difference between aspirin alone or aspirin 
in combination with LMWH 51.  
A recent meta-analysis comparing LMWH versus no LMWH for the prevention of recurrent 
placenta-mediated pregnancy complications in848 pregnant women with a previous history 
placental-mediated pregnancy complications showed a relative risk reduction of 0.52 (95% 
CI, 0.32 to 0.86) in women treated with LMWH52. The meta-analysis did not confirm any 
reduction of early pregnancy loss (<20 weeks) in patients with prior placenta-mediated 
pregnancy complications, whereas a statistically non-significant reduction in late pregnancy 
loss (>20 weeks) was observed 52.  
Very recently, results from a multicentre randomised controlled trial on 150 mg aspirin once 
daily versus placebo conducted in 1776 pregnant women at high risk for preterm pre-
eclampsia has shown to reduce the risk of preterm preeclampsia before week 34 of 
gestation significantly (1,6% versus 4,3%, OR 0.38, 95th CI 0.20-0.74; p=0.004) 53. 
 
MANAGEMENTOF ANTIPHOSPHOLIPID SYNDROME  
Thrombotic APS  
The current mainstay of treatment the thrombotic manifestations of APS is based on 
anticoagulation, including vitamin K antagonist (VKA) or heparin and antiplatelet therapy, 
such as low dose aspirin. Preliminary data supporting the use of direct oral anticoagulant 
(DOAC) in APS patients with previous venous thromboembolism is available, and other trials 
are also on-going, as yet the evidence base is incomplete to fully support the use of DOACs 
in APS. Very rarely immune modulating agents, immunosupression and anti-complement 
therapy are used in patients who do not respond to antithrombotic medication or in 
particularly severe conditions such as CAPS.  
ObstetricAPS  
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Pregnancy in APS are regarded as high risk pregnancies and the main aim of surveillance and 
treatment in pregnant women with aPL is to optimise maternal and fetal pregnancy 
outcomes. More specifically, the objective of antenatal care in pregnant patients with APS is 
close observation for maternal thrombosis, APS nephropathy, hypertension, proteinuria, 
other features of preeclampsia and to monitor fetal growth. 
Current standard of care for patients with obstetric APS includes treatment with low dose 
aspirin (LDA) (75-100 mg/day) and low molecular heparin (e.g., subcutaneous enoxaparin, 
dalteparin, nadroparin or subcutaneous tinzaparin) or unfractionated heparin. These 
recommendations are based on results from three randomised, controlled trials comparing 
LDA alone or in combination therapy with heparin in women with APS 54-56. Rai et al. showed 
a significantly higher rate of live births with LDA plus unfractionated heparin (5000 units BD) 
versus LDA alone (71% versus 42%; odds ratio, 3.37; 95% confidence interval, 1.40-8.10) 54. 
Similarly Kutteh et al., reported a significant improvement in the live birth rate with LDA and 
heparin versus LDA alone (80% versus 44%; p < 0.05) 56. However, no differences in outcome 
with combination therapy versus LDA was found in two other randomised trials, both using 
low molecular weight heparin (LMWH), with live birth rates approaching 80% in both arms. 
The heterogeneity in the conclusions seems attributable to the relatively poor outcomes in 
women receiving LDA only in the two former studies 55,57. Moreover, data from 
observational studies have reported 79%–100% pregnancy success rates with LDA alone in 
this subgroup of women 58. The current recommendation for the treatment of obstetric APS 
is to start with LDA and to escalate to additional LMWH if LDA alone is associated with 
pregnancy loss. Data to support this management have recently been published 10. 
 
PREGNANCY COUNSELLING AND SURVEILLANCE 
Overall there is agreement that pregnant women with obstetric APS require close education 
and monitoring of maternal and fetal health by a multidisciplinary team consisting of 
obstetricians, rheumatologists and haematologists with special interest in APS59,60. All 
women should be assessed regarding risk factors for venous thromboembolism and should 
receive thromboprophylaxis postpartum if indicated according to local guidelines. The Royal 
College of Gynaecology in the U.K. for example recommends for aPL positive women 
without clinical manifestations of APS 7 days post partum thromboprphylaxis and for 
women with APS this is extended to 6 weeks61. 
All women with APS can potentially give natural birth, unless there are obstetric reasons 
that suggest otherwise. Moreover, all women should be encouraged to stop smoking and to 
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reduce/cease their alcohol intake according to the national pregnancy guidelines. Patients 
with a recent thrombotic event in the last 3 months, particularly arterial, and/or 
uncontrolled hypertension should be encouraged to postpone further pregnancies8,24. 
Patients with severe pulmonary hypertension should be advised against pregnancy, because 
of the high risk of deterioration of such and the risk of maternal death8. 
Women with previous thrombosis should receive long-term anticoagulation once the risk of 
post-partum haemorrhage has settled. Both VKA and heparins are compatible with 
breastfeeding 62,63. With regards to fetal monitoring during pregnancy, bilateral uterine 
notching between 23 and 25 weeks' gestation has been shown to be an independent risk 
factor for the development of early-onset preeclampsia and gestational hypertension. Thus, 
bilateral uterine artery notching should be considered in the assessment of risk for the 
development of these pregnancy complications 64,65.  
Thrombotic risk assessment should also be considered in patients with a history of obstetric 
APS. Among other, Lefèvre et al. showed that patients with obstetric APS have a higher 
thrombotic risk when compared to healthy women (3.3 vs. 0–0.5/100 patient-years), even if 
treated with low-dose aspirin (LDA) 66. 
Similarly, in a 10-year observational study of 1592 women with pure obstetric APSand no 
history of thrombosis, Gris et al.67showed that LA was a risk factor for unprovoked proximal 
and distal deep and superficial vein thrombosis and similar results have been proved in 
other studies 68. 
 
 
TREATMENT PERSPECTIVES IN OBSTETRIC APS  
The current treatment regimens to prevent obstetric morbidity in APS have improved 
pregnancy outcome to a live birth rate of over 70% as mentioned above69. As 30% of women 
continue to have pregnancy complications,international groups are currently assessing 
different options in order to improve pregnancy outcomes in women with APS. The 
additional use of low dosesteroids has been assessed in refractory APS70. Intravenous 
immunoglobulin (IVIG) has been suggested to improve pregnancy complications in obstetric 
APS, with no significant improvement in pregnancy outcomes 71. 
Interesting data on pravastatin suggest a beneficial role in those women with established 
aPL-related PET. In their case series 11 patients treated with 20 mg pravastatin in addition to 
standard treatment, whereas the controls continued LDA and LWMH only. In all patients 
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exposed to pravastatin signs of pre-eclampsia, such as blood pressure and proteinuria 
improved and signs of placental perfusion remained stable without further deterioration 
compared to the control group13. 
The role of hydroxychloroquine (HCQ) has also been assessed. The immunmoldulatorHCQ  
may have beneficial effects not only in the management of thrombotic APS 72, but also in the 
prevention of pregnancy complications12,73,74. Clinical trials are eagerly awaited75.  The 
European randomised controlled multicenter trial ‘HYPATIA’will assess the role of HCQ 
versus placebo in pregnant women with aPL and hopefully provide more robust evidence on 
the use of HCQ in this setting 75. 
Complement activation,and therefore a potential role for eculizumab, has also been 
introduced as a potential target for APS therapy. The involvement of complement activation 
was first investigated in murine models of aPL-related pregnancy morbidities and growing 
evidences from both in vitro and in vivo studies are emerging37,38. Complement can be 
activated by the binding of C3 fragment to the Fc receptor of aPL antibodies or by the 
formation of autoantibodies against C1q, that are frequently detected in patients with APS76. 
The activation of complement pathway and consequently production of inflammatory 
molecules like C5a by aPL can directly activate platelets and monocytes, inducing the 
coagulation cascade, leading to the clinical manifestations of APS.  
Although in the current literature, several case reports describe the successful use of 
eculizumab in severe cases of APS, such as CAPS and cases of APS and thrombotic 
microangiopathy, the potential role of eculizumab should be further investigated 3. 
 
 
 
 
 
SUMMARY 
APS is the most frequent acquired risk factor for a treatable cause of recurrent first trimester 
pregnancy loss and increases the risk of conditions associated with ischemic placental 
dysfunction, including stillbirth, intrauterine death, pre-eclamspia, premature birth and fetal 
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growth restriction. The current standard of care for obstetric APS is based on aspirin and 
LMWH. In refractory APS, steroids may play a role to improve pregnancy outcomes. New 
approaches aiming to improve pregnancy outcomes include the immune-modulator HCQ. 
Atorvastatin may have some beneficial effect in women with established aPL-related pre-
eclampsia. Randomised controlled trials assessing these new treatment options are eagerly 
awaited. 
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